Financial Data and Key Metrics Changes - In 2024, the company achieved global net revenue of $266.3 million, a 32% increase over 2023, exceeding the guidance range of $260 million to $266 million [31] - The fourth quarter revenue was $79 million, reflecting a 30% increase compared to Q4 2023 [31] - The company reported a gross margin of 68.5% for the full year, with an adjusted gross margin of 69.6%, consistent with guidance [32] - Non-GAAP operating income for Q4 was $6.7 million, a significant improvement from a loss of $3.7 million in Q4 2023 [36] Business Line Data and Key Metrics Changes - The company added over 2,900 new accounts in 2024, bringing the total to more than 15,000 purchasing accounts, representing half of the toxin market [10] - The US market share approached 14% by the end of 2024, exceeding previous guidance [80] - The Evolys injectable gels are expected to contribute 8% to 10% of total revenue in 2025 [41] Market Data and Key Metrics Changes - The total addressable market for the company's products is approximately $6.2 billion, projected to grow to $10 billion by 2028 [40] - The company anticipates the US toxin market to grow in the mid to high single-digit range through 2028 [51] Company Strategy and Development Direction - The launch of Evolys is a top priority, with plans to commercialize in early Q2 2025 [13] - The company aims to achieve at least $700 million in revenue by 2028, with a non-GAAP operating income margin of at least 20% [20] - The company is focusing on integrating Evolys into its existing portfolio, leveraging a cash pay model and co-branded media benefits [17] Management's Comments on Operating Environment and Future Outlook - Management noted that despite challenging market conditions, the toxin market has shown consistent growth, particularly among younger consumers [48] - The company expressed confidence in its ability to capture market share and drive growth through innovative products and strategic partnerships [82] - Management highlighted the importance of the new weight loss label for Evolys, which is expected to attract new patients [52] Other Important Information - The company achieved profitability for the full year 2024, one year ahead of its goal [7] - The Evolys injectable gels utilize proprietary Coldex technology, which is expected to differentiate them from competitors [22] Q&A Session Summary Question: How does the company view the market conditions for US facial injectables? - Management acknowledged challenging market conditions but noted strong growth in the toxin market, particularly among younger consumers [48] Question: What are the expectations for the subscription model's performance? - The subscription model has shown good early results, but the company plans to wait for a full year cycle before sharing detailed metrics [56] Question: What are the growth expectations for the US toxin market in 2025? - Management projected a healthy growth rate for the toxin market, with expectations of mid to high single-digit growth [68] Question: How does the company plan to train accounts for the new Evolys products? - The company has developed a comprehensive training program and plans to train a significant number of accounts quickly [102] Question: What is the significance of the weight loss label for Evolys? - The weight loss label is expected to be a powerful marketing tool, attracting new patients seeking facial injectables [52]

Investment Rating - The industry investment rating is "Increase" (maintained) [9] Core Viewpoints - The report highlights the approval of China's first CaHA facial filler, Aphranel® by Moyang Bio, which is expected to perform well in the market due to its innovative micro-sphere structure and high biocompatibility [2] - Jinbo Bio reported a significant revenue increase of 85.40% year-on-year, reaching 1.447 billion yuan, with a net profit growth of 144.65% to 733 million yuan, driven by new product development and market expansion [3][4] - The report emphasizes the long-term potential for medical aesthetics penetration to continue increasing, suggesting a focus on companies like Giant Bio, Jinbo Bio, and others in the sector [9] Summary by Sections New Product Approvals - The report discusses the approval of Aphranel® as the first CaHA injection in China, noting its superior clinical performance and safety profile [2] - Jinbo Bio launched the world's first collagen net product, targeting eye area rejuvenation through advanced technology [4] Financial Performance - Jinbo Bio's financial results for 2024 show a revenue of 1.447 billion yuan, marking an 85.40% increase, and a net profit of 733 million yuan, reflecting a 144.65% growth [3] Market Trends - The report indicates a growing trend in the medical aesthetics market, with an expectation for increased penetration rates and competitive dynamics among brands [9] - It highlights the differentiation in cosmetic channels and the competitive landscape, suggesting that leading domestic brands are likely to continue outperforming [9]

以下文章来源于互联网那些事 ，作者互联网那些事 《2023年医美人群洞察报告》指出， 我国在2022年共有2093万名医美消费者，在2023年共有2354万 名医美消费者，涨幅数据为12.5%。倘若站在城市县级角度去观察市场，我们就会发现四级及以下城 市体验医美的人最多，用户占比数据高达38.4%。 黑医美围剿县城贵妇 随着人们生活水平的不断提高，医美已经不再是"都市丽人"和"时尚弄潮儿"的专属，它已经无缝融入 了普通人的日常消费版图。 这场消费趋势的"版本大更新"除了让医美市场规模突破了2300亿大关外，还吸引了部分黑心商人的目 光，间接导致这些不法逐利者将"黑医美"概念推向了乡镇、县域市场。 据光明网报道，较比于那些集中在大城市的医美乱象，如今寄生在乡镇的黑医美则更显狂野。 互联网那些事 . 新态度，深角度。 作者： 互联网那些事 来源： 互联网那些事（ID： hlw0823 ) 在这里，部分医美机构不仅没有登记注册，其相关人员也没有职业资格，堪称是彻头彻尾的"草台班 子"。 02 黑医美凭什么渗透县乡镇 和一线城市的医美消费群体不同，县乡医美的主流消费人群一般为40岁以上的中老年女性。这不仅意 味着县级 ...